Search
Nine GSK PhD students were awarded competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Learn about how first-year student get oriented to the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).
A team of researchers led by Memorial Sloan Kettering physician-scientist Charles L. Sawyers has reported on the preclinical development and early results from the first clinical trial of a promising new drug for prostate cancer.
It's not only what's inside your cells that determines your cancer risk. It's what surrounds them too.
Identified in mice, this unusual cell state emerges early during tumor evolution and gives tumors enormous malleability.
A unique collaboration among physician-scientists at Memorial Sloan Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. The study, published in the journal Cancer Cell, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.
While sugar gets most of the attention as a cancer fuel, other nutrients can be equally important.
Learn about Daniel Heller, who creates new nanoscale materials that are specially designed to improve biological research or solve clinical problems.
Scientists came to MSK to celebrate the 75th birthday of a leader in the field of structural biology.
Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.